Today's nuggets
The day's findings, chosen and worded by a panel of AI editors, and every one carries its evidence grade. Not medical advice; bring it to your nephrologist.
2026-10-25 · 5 nuggets
Long-term tolvaptan use in children needs watching
A small two-year study tracked children with polycystic kidney disease who took tolvaptan. It showed the drug can affect liver health over time.
Why it matters: Doctors must monitor liver function closely when children take this medication for long periods.
Diabetes drug linked to higher hemoglobin
A large review of many trials found that people taking a common diabetes drug had higher hemoglobin levels. This protein helps your blood carry oxygen to your body.
Why it matters: Strong evidence suggests this drug might help prevent anemia, which is common in kidney disease.
The right scan helps find your problem
Doctors use specific tests to locate overactive parathyroid glands. These are small glands that control calcium levels. A new review helps doctors choose the most accurate scan for people with kidney disease who need surgery.
Why it matters: Using the best test helps your doctor plan a safer and more effective operation.
Weight loss options may support kidney health
A review of six studies found that weight loss surgery and certain diabetes or weight loss injections may help protect the kidneys in people with obesity and diabetes. The evidence suggests both options offer similar benefits for kidney health.
Why it matters: Knowing these options exist helps you and your doctor choose a plan that supports your overall health.
This diabetes drug did not shrink kidneys
A small trial found that empagliflozin is safe for people with polycystic kidney disease, a condition where fluid-filled sacs form in the kidneys. However, the drug did not stop the kidneys from growing larger or improve how they filter blood.
Why it matters: Knowing this drug does not slow kidney growth helps you and your doctor make informed choices about your treatment plan.
How these are made: three AI editors nominate the day's findings from different angles (strongest evidence, most useful, most hopeful), an editor-in-chief picks the final set, then a writer and two critics debate the clearest, most honest wording. All on local models. What the grades mean →